Viking Global Investors
Viking Global Investors is a long/short equity hedge fund. The fund employs a bottom-up fundamental stock-picking strategy for its investments in equities in the U.S. and Europe. It focuses on the financial, telecommunication, media, technology, and consumer sectors. Viking Global Investors is based in New York and was founded in October, 1999 by Andreas Halvorsen, David Ott, and Brian Olson.
Messers. Halvorsen, Ott, and Olson worked together at Tiger Management Corp. All three left Tiger in early 1999.
View Older Stories View More Recent Stories
-
Chimera Appoints New CEO, Wins AFCR BRACE Award, and Accelerates towards the Clinic with TME-Modifying CAR-T Therapies for Solid Tumors
-
Form SC 13G STANDARD BIOTOOLS INC. Filed by: VIKING GLOBAL INVESTORS LP
-
Ginkgo Bioworks (DNA) and Elanco (ELAN) Launch BiomEdit
-
Elanco and Ginkgo Bioworks Launch BiomEdit, a New Animal Health Company Leveraging Microbiome Technology
-
Cazoo Announces Fourth Quarter and Full Year 2021 Financial Results
-
Horizon Technology Finance Leads $15 Million Venture Loan to MyForest Foods
-
Fluidigm (FLDM) Completes $250 Million Strategic Capital Infusion and Changes Name to Standard BioTools Inc.
-
Fluidigm Completes $250 Million Strategic Capital Infusion and Changes Name to Standard BioTools Inc.
-
Fluidigm (FLDM) Announces Stockholders Approve $250 Million Strategic Capital Infusion
-
Fluidigm Stockholders Approve $250 Million Strategic Capital Infusion
-
Fluidigm (FLDM) Announces Support Agreement with Caligan Partners Related to $250 Million Strategic Capital Infusion by Casdin Capital and Viking Global
-
Fluidigm Announces Support Agreement with Caligan Partners Related to $250 Million Strategic Capital Infusion by Casdin Capital and Viking Global
-
Fluidigm (FLDM) Highlights the Strategic Capital Infusion by Casdin Capital and Viking Global as the Only Actionable Financing Solution
-
Fluidigm Highlights the Strategic Capital Infusion by Casdin Capital and Viking Global as the Only Actionable Financing Solution
-
Fluidigm Adjourns Special Meeting of Stockholders Until April 1, 2022
-
Global Processing Services Announces New Partnership With Mastercard to Power ‘Next Generation Payments’ Technology to Global Fintechs
-
Form 4 PROCEPT BioRobotics Corp For: Mar 18 Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A PROCEPT BioRobotics Corp Filed by: VIKING GLOBAL INVESTORS LP
-
Fluidigm Urges Stockholders to Vote “FOR” ALL Proposals Related to $250 Million Strategic Capital Infusion TODAY
-
Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Fluidigm Stockholders Vote “FOR” ALL Proposals Related to $250 Million Strategic Capital Infusion
-
AlphaSense Taps Industry Veteran Melissa Sargeant as Chief Marketing Officer
-
Form SC 13D/A Ginkgo Bioworks Holdings Filed by: VIKING GLOBAL INVESTORS LP
-
Form D/A Viking Global Equities
-
Form D/A Viking Global Equities
-
Form D/A Viking Global Equities
-
FemTec Health Launches D2C Brand Awesome Woman to Bring Personalized Health and Wellness to Women in All Life Stages
-
Independence Blue Cross and Patina announce agreement to offer Medicare Advantage members a new primary care experience
-
FemTec Health Taps GeniusRx as Exclusive Online Pharmacy Partner for D2C Platform Awesome Woman
-
Fluidigm (FLDM) Reports Q4 Revenue of $38.3M, Net Loss of $0.8M
-
Fluidigm Announces Fourth Quarter and Full Year 2021 Financial Results
-
Goldman Sachs Appoints AlphaSense as the Exclusive Distributor of its Aftermarket Research
-
Form SC 13G/A Athira Pharma, Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A AbCellera Biologics Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Nuance Communications, Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A 4D Molecular Therapeutic Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Edgewise Therapeutics, Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A PMV Pharmaceuticals, Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A FIGS, Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Coupa Software Inc Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Talaris Therapeutics, Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Rallybio Corp Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A PROCEPT BioRobotics Corp Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Pharvaris N.V. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Mudrick Capital Acquisit Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Inhibrx, Inc. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Orion Acquisition Corp. Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Adaptive Biotechnologies Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G/A Zentalis Pharmaceuticals Filed by: VIKING GLOBAL INVESTORS LP
-
Form SC 13G Roivant Sciences Ltd. Filed by: VIKING GLOBAL INVESTORS LP
-
Form 13F-HR VIKING GLOBAL INVESTORS For: Dec 31

